133550-41-1

AG 556 is a highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TK inhibitor). AG 556 has been shown to decrease human atrial IKur and cloned hKv1.5 channels by inhibiting EGFR TK.

Epidermal growth factor receptor (EGFR) kinase inhibitor (IC 50 = 1.1 μ M). Selective over ErbB2 (IC 50 > 500 μ M).

[1]. zhang dy, zhang yh, sun hy, et al. epidermal growth factor receptor tyrosine kinase regulates the human inward rectifier potassium k(ir)2.3 channel, stably expressed in hek 293 cells. br j pharmacol, 2011 nov, 164(5): 1469-1478
[1].
[2]. zhang dy, wu w, deng xl, et al. genistein and tyrphostin ag556 inhibit inwardly-rectifying kir2.1 channels expressed in hek 293 cells via protein tyrosine kinase inhibition. biochim biophys acta, 2011, 1808(8): 1993-1999.
[3]. kleinberger-doron n, shelah n, capone r, et al. inhibition of cdk2 activation by selected tyrphostins causes cell cycle arrest at late g1 and s phase. exp cell res, 1998, 241(2): 340-351.
[4]. sevransky je, shaked g, novogrodsky a, et al. tyrphostin ag 556 improves survival and reduces multiorgan failure in canine escherichia coli peritonitis. j clin invest, 1997, 99(8): 1966-1973.